AI radiotherapy work advances: Siemens Healthineers stock stands at EUR 46.6 billion
Published on 10/23/2026 at 09:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRadiotherapy and reporting dates
- On October 21, Siemens Healthineers and NVIDIA announced an adaptive radiotherapy collaboration.
- Third-quarter 2026 revenue reached EUR 5.76 billion, up 1.80 percent year over year.
- Siemens Healthineers stock trades at EUR 41.63 at 9:40 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.31 percent below the Xetra close of October 22, 2026.
- The next quarterly report and analyst call are scheduled for November 5, 2026.
Siemens Healthineers (ISIN DE000SHL1006) is advancing AI-enabled radiotherapy while its market capitalization stands at EUR 46.6 billion as of October 23, 2026. On October 21, NVIDIA reported that the companies were collaborating on adaptive radiotherapy using agentic co-planning, patient-specific simulation and real-time computing.
Three milestones shape the story
On September 28, Siemens Healthineers introduced Accela, a radiotherapy system designed to deliver multi-site stereotactic treatment in as little as 60 seconds, according to Simply Wall St. On October 18, the company joined a radiopharmaceutical think tank, while its stock was up 17.30 percent over 90 days, the same source reported. On October 21, the NVIDIA collaboration became the latest event in that sequence.
What does the collaboration change?
The project is exploratory rather than a disclosed revenue contract. Its investor relevance lies in the combination of Siemens Healthineers' imaging and oncology expertise with NVIDIA computing, including Nemotron models, CUDA-accelerated dose calculation and Holoscan sensor processing, as described by Siemens Healthineers. The potential payoff is faster treatment planning, but commercialization and feature availability remain dependent on development and regulatory progress.
Operational execution remains the nearer test. In the third quarter of fiscal 2026, revenue was EUR 5.76 billion, up 1.80 percent from the prior-year quarter, while net income reached EUR 669.0 million and diluted earnings per share were EUR 0.60, according to Simply Wall St. Those figures give the AI initiative a financial backdrop, but they do not quantify any contribution from the NVIDIA work.
Next reporting date is November 5
Siemens Healthineers lists its next quarterly results and analyst call for November 5, 2026, followed by a US roadshow on November 6, 2026, on its investor-relations page. The report will show whether Diagnostics weakness and growth in Imaging are changing the fiscal-year picture.
Stock price and investor view
At 9:40 a.m. CEST on October 23, 2026, Siemens Healthineers stock was trading at EUR 41.63 at Lang & Schwarz, 0.31 percent below the Xetra close of October 22, 2026 at EUR 41.76. The modest move leaves the November report as the next concrete test for the operating thesis. The further course of trading is shown by the continuously updated real-time quote of Siemens Healthineers stock.
Siemens Healthineers stock facts
- Company: Siemens Healthineers AG
- ISIN: DE000SHL1006
- Ticker: SHL
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 23, 2026, 9:40 a.m. CEST): EUR 41.63
- Change versus Xetra close: minus 0.31 percent
- Xetra close (October 22, 2026): EUR 41.76
- Market capitalization: EUR 46.6 billion (as of October 23, 2026)
- 52-week range: EUR 32.81-49.71 (as of October 22, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Next earnings date: November 5, 2026
Market context: Market report DAX.
